CTOs on the Move

Total Joint Orthopedics

www.tjoinc.com

 
Total Joint Orthopedics (TJO) makes high-quality, efficient implants for hip and knee replacement. Our streamlined instrumentation is intuitive and easy to use for reproducible results.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Saranas

Early Bird is the first and only FDA-approved bleed detection system for peri and post-procedural monitoring of endovascular procedures.

Rehab 2 Perform

R2P creates a unique physical therapy experience, offering our blend of performance, return to sport, physical therapy, dry needling and injury prevention.

Unisource NTC

Unisource NTC is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.

Cerevel

Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson`s, Alzheimer`s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.